Ulcerative Colitis
Chronic inflammatory bowel disease causing colonic mucosal inflammation. MSC therapy promotes mucosal healing and restores immune tolerance in the gut.
Ulcerative colitis is a chronic inflammatory bowel disease characterized by continuous mucosal inflammation and ulceration of the colon and rectum. Affecting over 1 million Americans, UC causes bloody diarrhea, abdominal cramping, urgency, and — in severe cases — life-threatening colitis requiring emergency colectomy. The disease follows a relapsing-remitting course and substantially impairs quality of life.
UC is driven by a failure of immune tolerance to the commensal gut microbiome, with Th2 and innate immune pathways producing an excessive inflammatory response at the mucosal barrier. Standard therapy progresses through aminosalicylates, corticosteroids, immunomodulators, and biologics (anti-TNF, anti-integrin, anti-IL-12/23) — but 30–40% of patients are refractory to available therapies and face surgical colectomy.
MSC therapy represents one of the most promising experimental approaches for refractory UC — targeting mucosal immune dysregulation at a fundamental level and promoting the gut barrier repair that conventional therapy cannot achieve.
MSCs exert multi-layered therapeutic effects in UC: they reduce colonic mucosal inflammation by suppressing NF-κB activation in epithelial cells, shifting macrophage polarization toward anti-inflammatory M2 phenotype, and expanding colonic Treg populations that enforce mucosal immune tolerance. They also secrete EGF, KGF, and hepatocyte growth factor — promoting epithelial restitution and mucosal barrier repair.
Multiple clinical trials of allogeneic MSC infusion in UC — including a Phase I/II study published in Gastroenterology — have demonstrated clinical response (defined as reduction in Mayo score) in patients refractory to standard therapies, with endoscopic mucosal healing observed in a subset. Some patients achieved clinical remission without escalation to colectomy.
True Regen coordinates colonoscopy reports, fecal calprotectin, Mayo score assessment, and inflammatory marker panel at baseline and follow-up to document mucosal and clinical response. Each UC case is reviewed by Regen Cord's clinical team before protocol enrollment.
- Clinical response (reduction in Mayo score)
- Endoscopic mucosal healing
- Decreased rectal bleeding and stool frequency
- Reduced fecal calprotectin and CRP
- Sustained remission without escalation to surgery
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.